NCT07581158 Understanding and Targeting Self-Regulatory Control in Bulimia Nervosa
| NCT ID | NCT07581158 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Bulimia Nervosa |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-06-17 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-06-17 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the effects of noninvasive prefrontal cortex (PFC) neurofeedback during eating in women with bulimia nervosa (BN) using wearable brain imaging, functional near-infrared spectroscopy (fNIRS), together with a brain-based 4-week text-messaging intervention. The investigators will examine how these interventions may influence inhibitory control and eating disorder symptoms in women with bulimia nervosa.
Eligibility Criteria
Inclusion criteria: * Female * Aged 18 to 55 years * Meet diagnostic criteria for bulimia nervosa (BN) or BN of low frequency and/or limited duration * Current body mass index greater than or equal to 18.5kg/m2 but under 40kg/m2 * English-speaking Exclusion criteria: * Ongoing medical treatment or planned/recent change in medical treatment, major medical condition, or psychiatric disorder that may interfere with study variables or participation * Current psychotherapy focused primarily on eating disorder symptoms * Pregnancy or planned pregnancy, or lactation during the study period * Allergy to ingredients in the shake
Contact & Investigator
Laura A. Berner, Ph.D.
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT07581158 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 55 Years, studying Bulimia Nervosa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07581158 currently recruiting?
Yes, NCT07581158 is actively recruiting participants. Contact the research team at sila.sozeri@mssm.edu for enrollment information.
Where is the NCT07581158 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07581158 clinical trial?
NCT07581158 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Laura A. Berner, Ph.D. at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 40 participants.